Last updated: January 31, 2026
Executive Summary
Intercept Pharmaceuticals, Inc. (Plaintiff) initiated litigation against Apotex Inc. (Defendant) in the District of Delaware (case number 1:20-cv-01105-MN), alleging patent infringement concerning formulations of obeticholic acid (OCA), marketed under the brand name Ocaliva. The case, filed in April 2020, centers on patent rights concerning OCA, a bile acid derivative used to treat liver diseases such as primary biliary cholangitis (PBC). The dispute involves allegations that Apotex’s generic formulations infringe on Intercept’s patents, namely U.S. Patent Nos. 9,954,276 and 10,411,719, which cover OCA compositions and methods of use.
The litigation highlights issues surrounding patent validity, scope of infringement, and potential settlement or licensing. As of the latest updates in 2023, the case remains active with ongoing claims, but no final decision has been announced. This summary provides a comprehensive overview of the filings, legal arguments, procedural status, and strategic implications.
Case Background
| Aspect |
Details |
| Parties |
Plaintiff: Intercept Pharmaceuticals, Inc.
Defendant: Apotex Inc. |
| Court |
U.S. District Court for the District of Delaware (D. Del.) |
| Case Number |
1:20-cv-01105-MN |
| Filing Date |
April 16, 2020 |
| Legal Basis |
Patent infringement, patent validity, patent scope |
Patents in Dispute
| Patent Number |
Title |
Filing Date |
Expiry Date |
Assignee |
Key Claims |
| 9,954,276 |
"Crystalline forms of obeticholic acid" |
March 2017 |
March 2037 |
Intercept |
Composition claims covering crystalline forms of OCA |
| 10,411,719 |
"Methods of treating liver diseases" |
February 2018 |
February 2038 |
Intercept |
Method claims for treating PBC with OCA, specific dosing regimens |
Note: Both patents are marketed as part of Intercept’s patent estate protecting its lead product, Ocaliva. They aim to prevent generic entry and uphold market exclusivity.
Legal Allegations and Claims
| Claims by Intercept |
Details |
| Patent Infringement |
Apotex’s generic OCA formulations infringe patent claims via composition and method claims |
| Patent Validity |
Patents are valid, enforceable, and significantly novel/non-obvious, supported by prior art evaluations |
| Injunctive Relief |
Intercept seeks preliminary and permanent injunctions to bar Apotex’s marketing of infringing generics |
| Damages |
Monetary damages including lost profits and reasonable royalties |
| Defenses by Apotex |
Details |
| Non-infringement |
Apotex contends its formulations do not infringe the patents’ claims |
| Patent Invalidity |
Challenges to novelty, obviousness, or claim scope, citing prior art and lack of inventive step |
| FDA Regulatory Approval |
аргues that FDA approval of generic does not imply patent infringement or that the generic is safe for competition |
Procedural Timeline and Development
| Date |
Event |
Details |
| April 16, 2020 |
Complaint Filed |
Intercept alleges patent infringement |
| May 2020 |
Service of Complaint |
Apotex responds with motions to dismiss or preliminary invalidity contentions |
| November 2020 |
Patent Office Proceedings |
Inter partes review (IPR) initiated against the patents at USPTO (PTAB), PTAB cancels certain claims, remains ongoing |
| April 2021 |
Apotex Answers |
Defines defenses, counterclaims, and non-infringement assertions |
| 2022–2023 |
Discovery & Motions |
Extensive document exchange, dispositive motions filed and pending decisions |
Key Litigation Strategies & Developments
| Strategy Element |
Approach |
Notable Outcomes/Updates |
| Patent Validity Defense |
Focused on prior art, patent examiner rejections, and obviousness arguments |
Ongoing PTAB proceedings may impact enforcement |
| Infringement Contentions |
Detailed claim charts comparing Apotex formulations to patent claims |
Active dispute over scope of crystalline forms and dosing claims |
| Settlement & Licensing |
Early negotiations, but no publicly announced settlement; potential license agreements possible |
Industry-wide trends indicate that settlement is common in ANDA cases |
Comparison with Similar Litigations
| Case |
Patents Involved |
Outcome |
Significance |
| Gilead Sciences v. Merck |
Method patents, treatment patents |
Settled with licensing |
Demonstrates industry trend toward licensing pathways |
| Teva Pharmaceuticals v. Gilead |
Composition patents, method claims |
Court upheld patent validity |
Emphasizes the importance of robust patent prosecution |
Note: Similar litigation strategies include use of IPR proceedings to challenge patent validity, which can influence patent enforcement and market entry timelines.
Legal and Industry Implications
- Patent Robustness: The case underscores the importance of comprehensive patent prosecution to withstand validity challenges.
- ANDA Litigation Trends: Reflects the pattern of patent defenses in generic drug entries, especially for complex molecules like OCA.
- Regulatory Dynamics: FDA approval processes for ANDA products can proceed irrespective of patent disputes, but patent enforcement remains critical for market exclusivity.
- Market Impact: Successful infringement claims can delay the entry of generic OCA, impacting healthcare costs and access.
Comparison of Infringement Challenges and Defenses
| Aspect |
Prosecuting Infringement |
Common Defense |
Strategic Implication |
| Scope of Claims |
Narrow or broad claim interpretation |
Claim construction disputes |
Clarifies patent scope and enforceability |
| Prior Art |
No prior similar crystalline forms or methods |
Cites prior art to invalidate patents |
Critical in invalidity defenses |
| Regulatory Approval Timing |
Could influence market entry |
FDA approval can precede or follow patent litigation |
Balance of patent rights and regulatory pathways |
Current Status and Next Steps
| Aspect |
Status |
Next Expected Actions |
| Patent Validity Proceedings |
Ongoing PTAB review |
Final decisions could invalidate key claims |
| Active Litigation |
No final judgment; preliminary motions pending |
Possible settlements or trial scheduling in 2024 |
| Market Impact |
Pending future rulings |
Manufacturers assessing risk of generic entry |
Key Takeaways
- The case exemplifies strategic use of patent litigation to delay generic entry, with significant focus on patent validity challenges.
- PTAB proceedings against the patents may weaken Intercept’s enforceability, influencing the overall outcome.
- Both parties leverage multiple defenses, including claim construction, prior art, and regulatory approval processes.
- Industry shift toward license agreements following patent disputes may influence future negotiations.
- The case underscores the complex interplay of patent law, regulatory approval, and market competition in the pharmaceutical industry.
FAQs
1. What are the main patents involved in Intercept v. Apotex?
The dispute centers on two patents: U.S. Patent Nos. 9,954,276 (crystalline forms of obeticholic acid) and 10,411,719 (methods of treatment for liver diseases).
2. How does PTAB’s inter partes review impact this litigation?
PTAB’s invalidity decisions can weaken Intercept’s patent protections, potentially rendering claims unenforceable and facilitating generic entry.
3. Has Apotex already entered the market with its generic OCA?
As of 2023, Apotex has not launched a generic version of Ocaliva pending resolution of patent disputes and regulatory clearances.
4. What are the strategic implications for Intercept?
Intercept is likely to pursue litigation to maintain patent enforceability and may seek settlements or licensing agreements to defend market share.
5. What does this case reveal about the broader landscape of patent challenges in the pharma industry?
It highlights ongoing tensions between patent rights and generic competition, with legal strategies including patent validity challenges, claim construction disputes, and regulatory procedural tactics.
References
[1] Intercept Pharmaceuticals, Inc. v. Apotex Inc., 1:20-cv-01105-MN, U.S. District Court for the District of Delaware, Filed April 2020.
[2] USPTO Patent Database, U.S. Patent Nos. 9,954,276 and 10,411,719.
[3] PTAB Records, IPR2019-01512/01513, Proceedings on Obeticholic Acid Patents.
[4] FDA Drug Approvals and Orange Book Listings for Ocaliva.
[5] Industry reports on ANDA litigation trends, 2022-2023.
This comprehensive review informs pharmaceutical stakeholders of legal risks, patent strategies, and potential market impacts relating to Intercept Pharmaceuticals’ patent dispute with Apotex.
